Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients With Patent Foramen Ovale (PFO) - The Gore REDUCE Clinical Study

NCT00738894 is registered in ClinicalTrials.gov with W.L.Gore & Associates as lead sponsor.

NCT NCT00738894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00738894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients With Patent Foramen Ovale (PFO) - The Gore REDUCE Clinical Study
Lead sponsor
W.L.Gore & Associates
Phase
Not applicable
Overall status
Completed
Start date
December 10, 2008
Completion date
May 11, 2020
Enrollment
664 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stroke, transient ischemic attack